Shares of Sun Pharmaceutical Industries extended gains and rose 1.8 percent to a 52-week high of Rs 1,781.5 on August 23 after the company said that it launched an antibacterial treatment in India under the brand name STARIZO (Tedizolid Phosphate). This new medication is designed to combat Acute Bacterial Skin and Skin Structure Infections (ABSSSI), particularly those caused by drug-resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA).
At 2.30 PM, shares of Sun Pharma were trading 1.7 percent higher at Rs 1,780 apiece. The stock has gained 14 percent in the past six months, slightly outperforming the Nifty 50, which gained 12 percent during the same period. Sun Pharma has been giving positive weekly returns for the past five weeks.
Sun Pharma has acquired the rights from Merck, Sharp & Dohme (MSD) to develop, manufacture, and commercialise Tedizolid Phosphate in India.
Follow our live blog for all the market action
"Drug-resistant bacteria such as Methicillin-Resistant Staphylococcus Aureus (MRSA) causing
ABSSSIs, are more challenging to treat due to the limited availability of effective treatment options in hospitals," said Kirti Ganorkar, CEO of India Business, Sun Pharma. "With STARIZO, we are introducing a treatment option which is effective and has the convenience of once-a-day dosing," he said.
ABSSSIs are a prevalent type of infection, accounting for approximately 29-32 percent of all infections in India between 2018 and 2019. MRSA rates have been increasing each year in India.
Also Read | Accumulate Sun Pharmaceutical Industries; target of Rs 1827: KR Choksey
STARIZO is a once-a-day oral medication that needs to be taken for just six days, compared to the current standard of care, which often requires a twice-daily regimen for 10-14 days, Sun Pharma said.
Tedizolid Phosphate is available in India under a licensing agreement with Merck Sharp & Dohme Singapore Trading Pte Ltd.
Sun Pharma is a global specialty generics company with a presence in innovative products, generics, and consumer healthcare. It is the largest pharmaceutical company in India and a leading generic company in the US and global emerging markets.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
